OLIVERO, Martina
OLIVERO, Martina
ONCOLOGIA
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells
2018-01-01 Olivero, Martina; Erriquez, Jessica; Arigoni, Maddalena; Capellero, Sonia; D'Ambrosio, Concetta; Mittica, Gloria; Borella, Fulvio; Katsaros, Dionyssios; Privitera, Silvana; Berrino, Enrico; Venesio, Tiziana; Valabrega, Giorgio; Calogero, Raffaele; Renzo, Maria Flavia Di
Albright hereditary osteodystrphy and pseudohypoparathyroidism: three new mutation and common deletion in GNAS1.
2000-01-01 De Sanctis L; Romagnolo De Sanctis C; Lala R; Olivero M; Di Renzo MF; Dianzani I.
Attivazione e caratterizzazione molecolare dell’oncogene AKT nei tumori mammari felini.
2009-01-01 Maniscalco L.; De Maria R.; Iussich S.; Martín De Las Mulas J.; Olivero M.; Millán Y; Biolatti B.
Cisplatin unveils cancer cell addiction to the non-oncogene CDT2
2009-01-01 Olivero M; Dettori D; Lorenzato A; Martino C; Musiani D; Orlando G; Di Renzo MF
CSE1L as a Potential Target to Sensitize Ovarian Cancer Cells to Cisplatin
2010-01-01 Lorenzato A; Olivero M; Calogero R., Martino C, Musiani D, Dani N, Di Renzo MF
DNA damage stress phenotype makes cancer cells addicted to a redundant CUL4 dependent pathway
2011-01-01 Olivero M; Dettori D; Pavan S; Di Renzo MF
Genetics in renal cancer
2008-01-01 M. Olivero; A. Lorenzato; Di Renzo MF
HSP27 is Involved in Ovarian Cancer Cell Motility and Response to Paclitaxel
2012-01-01 Pavan S ; Musiani D ; Torchiaro E ; Migliardi G ; Olivero M; Di Renzo MF
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs)
2018-01-01 Concetta D’Ambrosio, Martina Olivero, Jessica Erriquez, Maddalena Arigoni, Sonia Capellero, Gloria Mittica, Fulvio Borella, Dionyssios Katsaros, Silvana Privitera, Enrico Berrino, Tiziana Vanesio, Stefania Bolla, Giorgio Valabrega, Raffaele Calogero and Maria Flavia Di Renzo
Inhibition of P90RSK Sensitizes Ovarian Cancer Cells to Apoptosis
2012-01-01 Torchiaro E ; Olivero M ; Pavan S ; Di Renzo MF
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma
2009-01-01 Raffaella De Maria; Silvia Miretti; Selina Iussich; Martina Olivero;Emanuela Morello; Andrea Bertotti; James G. Christensen; Bartolomeo Biolatti; Roy A. Levine; Paolo Buracco; Maria Flavia Di Renzo
MET-oncogene transforms human bone-derived cells by targeting committed progenitors.
2010-01-01 Dani N; Olivero M; Lorenzato A; Cuvertino S; Patane’ S; Van Duist M; Mareschi K; Fagioli F; Di Renzo MF
MET-ONCOGENE TRANSFORMS HUMAN PRIMARY BONE-DERIVED CELLS BY TARGETING OSTEOPROGENITORS
2010-01-01 N Dani; M Olivero; S Patane; M VanDuist; K Mareschi(1); F Fagioli(1); Di Renzo MF
Molecular characterization and activation of AKT oncogene in feline mammary tumors
2009-01-01 Maniscalco Lorella; Raffaella De Maria ; Selina Iussich ; Minelli Carla; Olivero Martina; Sasaki Nobu; Bartolomeo Biolatti
Overexpression of c.Met oncogene in canine osteosarcomas and cells lines
2006-01-01 RAFFAELLA DE MARIA; SILVIA MIRETTI; SELINA IUSSICH; MARTINA OLIVERO; MARIA FLAVIA DI RENZO; PAOLO BURACCO; BARTOLOMEO BIOLATTI
P38MAPK highlights the dark side of Met/HGF pathway in ovarian cancer
2007-01-01 Lorenzato A; Coltella N; Olivero M; Martino C; Dettori D; Cossu C; Calogero R; Di Renzo MF
Quantitative HER2/neu gene expression in feline mammary tumors
2004-01-01 RAFFAELLA DE MARIA; SELINA IUSSICH; MARTINA OLIVERO; TOMAOKI MURATA; B. BIOLATTI; MASSIMO CASTAGNARO; BARTOLOMEO BIOLATTI
Results of 149 mobile bearing postero-stabilized TKA at average of 7 years follow-up: analysis of prognostic factors influencing outcomes.
2016-01-01 Rosso F, Cottino U, Olivero M, Dettoni F, Bruzzone M, Bonasia DE, Rossi R
Shortening of the bones of the hand in genetically characterized PHP-la patients.
2002-01-01 De Sanctis L; Romagnolo D; Andreo MR; Olivero M; Dianzani I; De Sanctis C.
The cellular apoptosis susceptibility CAS/CSE1L gene specifically protects ovarian cancer cells from death by suppressing RASSF1C
2011-01-01 Lorenzato A; Martino C; Olivero M; Dani N; Oligschläger Y; Ferrero AM; Biglia N; Calogero R; Di Renzo MF
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells | 2018 | Olivero, Martina; Erriquez, Jessica; Arigoni, Maddalena; Capellero, Sonia; D'Ambrosio, Concetta; Mittica, Gloria; Borella, Fulvio; Katsaros, Dionyssios; Privitera, Silvana; Berrino, Enrico; Venesio, Tiziana; Valabrega, Giorgio; Calogero, Raffaele; Renzo, Maria Flavia Di | |
| Albright hereditary osteodystrphy and pseudohypoparathyroidism: three new mutation and common deletion in GNAS1. | 2000 | De Sanctis L; Romagnolo De Sanctis C; Lala R; Olivero M; Di Renzo MF; Dianzani I. | |
| Attivazione e caratterizzazione molecolare dell’oncogene AKT nei tumori mammari felini. | 2009 | Maniscalco L.; De Maria R.; Iussich S.; Martín De Las Mulas J.; Olivero M.; Millán Y; Biolatti B. | |
| Cisplatin unveils cancer cell addiction to the non-oncogene CDT2 | 2009 | Olivero M; Dettori D; Lorenzato A; Martino C; Musiani D; Orlando G; Di Renzo MF | |
| CSE1L as a Potential Target to Sensitize Ovarian Cancer Cells to Cisplatin | 2010 | Lorenzato A; Olivero M; Calogero R., Martino C, Musiani D, Dani N, Di Renzo MF | |
| DNA damage stress phenotype makes cancer cells addicted to a redundant CUL4 dependent pathway | 2011 | Olivero M; Dettori D; Pavan S; Di Renzo MF | |
| Genetics in renal cancer | 2008 | M. Olivero; A. Lorenzato; Di Renzo MF | |
| HSP27 is Involved in Ovarian Cancer Cell Motility and Response to Paclitaxel | 2012 | Pavan S ; Musiani D ; Torchiaro E ; Migliardi G ; Olivero M; Di Renzo MF | |
| Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) | 2018 | Concetta D’Ambrosio, Martina Olivero, Jessica Erriquez, Maddalena Arigoni, Sonia Capellero, Gloria Mittica, Fulvio Borella, Dionyssios Katsaros, Silvana Privitera, Enrico Berrino, Tiziana Vanesio, Stefania Bolla, Giorgio Valabrega, Raffaele Calogero and Maria Flavia Di Renzo | |
| Inhibition of P90RSK Sensitizes Ovarian Cancer Cells to Apoptosis | 2012 | Torchiaro E ; Olivero M ; Pavan S ; Di Renzo MF | |
| met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma | 2009 | Raffaella De Maria; Silvia Miretti; Selina Iussich; Martina Olivero;Emanuela Morello; Andrea Bertotti; James G. Christensen; Bartolomeo Biolatti; Roy A. Levine; Paolo Buracco; Maria Flavia Di Renzo | |
| MET-oncogene transforms human bone-derived cells by targeting committed progenitors. | 2010 | Dani N; Olivero M; Lorenzato A; Cuvertino S; Patane’ S; Van Duist M; Mareschi K; Fagioli F; Di Renzo MF | |
| MET-ONCOGENE TRANSFORMS HUMAN PRIMARY BONE-DERIVED CELLS BY TARGETING OSTEOPROGENITORS | 2010 | N Dani; M Olivero; S Patane; M VanDuist; K Mareschi(1); F Fagioli(1); Di Renzo MF | |
| Molecular characterization and activation of AKT oncogene in feline mammary tumors | 2009 | Maniscalco Lorella; Raffaella De Maria ; Selina Iussich ; Minelli Carla; Olivero Martina; Sasaki Nobu; Bartolomeo Biolatti | |
| Overexpression of c.Met oncogene in canine osteosarcomas and cells lines | 2006 | RAFFAELLA DE MARIA; SILVIA MIRETTI; SELINA IUSSICH; MARTINA OLIVERO; MARIA FLAVIA DI RENZO; PAOLO BURACCO; BARTOLOMEO BIOLATTI | |
| P38MAPK highlights the dark side of Met/HGF pathway in ovarian cancer | 2007 | Lorenzato A; Coltella N; Olivero M; Martino C; Dettori D; Cossu C; Calogero R; Di Renzo MF | |
| Quantitative HER2/neu gene expression in feline mammary tumors | 2004 | RAFFAELLA DE MARIA; SELINA IUSSICH; MARTINA OLIVERO; TOMAOKI MURATA; B. BIOLATTI; MASSIMO CASTAGNARO; BARTOLOMEO BIOLATTI | |
| Results of 149 mobile bearing postero-stabilized TKA at average of 7 years follow-up: analysis of prognostic factors influencing outcomes. | 2016 | Rosso F, Cottino U, Olivero M, Dettoni F, Bruzzone M, Bonasia DE, Rossi R | |
| Shortening of the bones of the hand in genetically characterized PHP-la patients. | 2002 | De Sanctis L; Romagnolo D; Andreo MR; Olivero M; Dianzani I; De Sanctis C. | |
| The cellular apoptosis susceptibility CAS/CSE1L gene specifically protects ovarian cancer cells from death by suppressing RASSF1C | 2011 | Lorenzato A; Martino C; Olivero M; Dani N; Oligschläger Y; Ferrero AM; Biglia N; Calogero R; Di Renzo MF |